Literature DB >> 27482289

Anti-androgen therapy in triple-negative breast cancer.

Valerie N Barton1, Michael A Gordon1, Jennifer K Richer1, Anthony Elias2.   

Abstract

Entities:  

Year:  2016        PMID： 27482289      PMCID： PMC4952024          DOI： 10.1177/1758834016646735

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  15 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Targeting androgen receptor in estrogen receptor-negative breast cancer.

Authors:  Min Ni; Yiwen Chen; Elgene Lim; Hallie Wimberly; Shannon T Bailey; Yuuki Imai; David L Rimm; X Shirley Liu; Myles Brown
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

3.  Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.

Authors:  Ana M Gonzalez-Angulo; Katherine Stemke-Hale; Shana L Palla; Mark Carey; Roshan Agarwal; Funda Meric-Berstam; Tiffany A Traina; Clifford Hudis; Gabriel N Hortobagyi; William L Gerald; Gordon B Mills; Bryan T Hennessy
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

4.  Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Authors:  Ayca Gucalp; Sara Tolaney; Steven J Isakoff; James N Ingle; Minetta C Liu; Lisa A Carey; Kimberly Blackwell; Hope Rugo; Lisle Nabell; Andres Forero; Vered Stearns; Ashley S Doane; Michael Danso; Mary Ellen Moynahan; Lamia F Momen; Joseph M Gonzalez; Arooj Akhtar; Dilip D Giri; Sujata Patil; Kimberly N Feigin; Clifford A Hudis; Tiffany A Traina
Journal:  Clin Cancer Res       Date:  2013-08-21       Impact factor: 12.531

5.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Authors:  Cornelia Liedtke; Chafika Mazouni; Kenneth R Hess; Fabrice André; Attila Tordai; Jaime A Mejia; W Fraser Symmans; Ana M Gonzalez-Angulo; Bryan Hennessy; Marjorie Green; Massimo Cristofanilli; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

6.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Authors:  Ingo K Mellinghoff; Igor Vivanco; Andrew Kwon; Chris Tran; John Wongvipat; Charles L Sawyers
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

7.  A refined molecular taxonomy of breast cancer.

Authors:  M Guedj; L Marisa; A de Reynies; B Orsetti; R Schiappa; F Bibeau; G MacGrogan; F Lerebours; P Finetti; M Longy; P Bertheau; F Bertrand; F Bonnet; A L Martin; J P Feugeas; I Bièche; J Lehmann-Che; R Lidereau; D Birnbaum; F Bertucci; H de Thé; C Theillet
Journal:  Oncogene       Date:  2011-07-25       Impact factor: 9.867

8.  Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Authors:  Dawn R Cochrane; Sebastián Bernales; Britta M Jacobsen; Diana M Cittelly; Erin N Howe; Nicholas C D'Amato; Nicole S Spoelstra; Susan M Edgerton; Annie Jean; Javier Guerrero; Francisco Gómez; Satyanarayana Medicherla; Iván E Alfaro; Emma McCullagh; Paul Jedlicka; Kathleen C Torkko; Ann D Thor; Anthony D Elias; Andrew A Protter; Jennifer K Richer
Journal:  Breast Cancer Res       Date:  2014-01-22       Impact factor: 6.466

9.  Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.

Authors:  Mark Kriegsmann; Volker Endris; Thomas Wolf; Nicole Pfarr; Albrecht Stenzinger; Sibylle Loibl; Carsten Denkert; Andreas Schneeweiss; Jan Budczies; Peter Sinn; Wilko Weichert
Journal:  Oncotarget       Date:  2014-10-30

10.  PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.

Authors:  Brian D Lehmann; Joshua A Bauer; Johanna M Schafer; Christopher S Pendleton; Luojia Tang; Kimberly C Johnson; Xi Chen; Justin M Balko; Henry Gómez; Carlos L Arteaga; Gordon B Mills; Melinda E Sanders; Jennifer A Pietenpol
Journal:  Breast Cancer Res       Date:  2014-08-08       Impact factor: 6.466
View more
  9 in total

1.  Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study.

Authors:  Katarzyna J Jerzak; Nechama Lipton; Sharon Nofech-Mozes; Dina Boles; Elzbieta Slodkowska; Gregory R Pond; Ellen Warner
Journal:  Breast Cancer Res Treat       Date:  2021-07-27       Impact factor: 4.872

2.  Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy.

Authors:  Christian K Werner; Uchechi J Nna; Hanshi Sun; Kari Wilder-Romans; Joseph Dresser; Ayesha U Kothari; Weihua Zhou; Yangyang Yao; Arvind Rao; Stefanie Stallard; Carl Koschmann; Tarik Bor; Waldemar Debinski; Alexander M Hegedus; Meredith A Morgan; Sriram Venneti; Edwina Baskin-Bey; Daniel E Spratt; Howard Colman; Jann N Sarkaria; Arul M Chinnaiyan; Joel R Eisner; Corey Speers; Theodore S Lawrence; Roy E Strowd; Daniel R Wahl
Journal:  Mol Cancer Ther       Date:  2020-08-12       Impact factor: 6.261

3.  Retinoblastoma protein expression and its predictors in triple-negative breast cancer.

Authors:  Stuart J Schnitt; Nadine Tung; Jaymin M Patel; Andrew Goss; Judy E Garber; Vanda Torous; Edward T Richardson; Miriam J Haviland; Michele R Hacker; Gordon J Freeman; Tessa Nalven; Brian Alexander; Larissa Lee; Laura C Collins
Journal:  NPJ Breast Cancer       Date:  2020-06-05

4.  Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer.

Authors:  Alec M Chiu; Mithun Mitra; Lari Boymoushakian; Hilary A Coller
Journal:  Sci Rep       Date:  2018-08-07       Impact factor: 4.996

5.  Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells.

Authors:  Manuel Abreu; Pablo Cabezas-Sainz; Thais Pereira-Veiga; Catalina Falo; Alicia Abalo; Idoia Morilla; Teresa Curiel; Juan Cueva; Carmela Rodríguez; Vanesa Varela-Pose; Ramón Lago-Lestón; Patricia Mondelo; Patricia Palacios; Gema Moreno-Bueno; Amparo Cano; Tomás García-Caballero; Miquel Ángel Pujana; Laura Sánchez-Piñón; Clotilde Costa; Rafael López; Laura Muinelo-Romay
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

6.  Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.

Authors:  Toru Hanamura; Jessica L Christenson; Kathleen I O'Neill; Emmanuel Rosas; Nicole S Spoelstra; Michelle M Williams; Jennifer K Richer
Journal:  Breast Cancer Res       Date:  2021-11-04       Impact factor: 6.466

7.  Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.

Authors:  In Hae Park; Han Na Yang; Su Yeon Jeon; Jung-Ah Hwang; Min Kyeong Kim; Sun-Young Kong; Sung Hoon Shim; Keun Seok Lee
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

8.  TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel.

Authors:  Bantari Wk Wardhani; Meidi Utami Puteri; Yukihide Watanabe; Melva Louisa; Rianto Setiabudy; Mitsuyasu Kato
Journal:  J Exp Pharmacol       Date:  2020-01-23

9.  Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.

Authors:  Savitha Rajarajan; Aruna Korlimarla; Annie Alexander; C E Anupama; Rakesh Ramesh; B S Srinath; T S Sridhar; Jyothi S Prabhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.